@article{AldejohannWiesePosseltGastmeieretal.2022,
  author    = {Aldejohann, Alexander Maximilian and Wiese-Posselt, Miriam and Gastmeier, Petra and Kurzai, Oliver},
  title     = {Expert recommendations for prevention and management of Candida auris transmission},
  series = {Mycoses},
  volume    = {65},
  journal   = {Mycoses},
  number    = {6},
  doi       = {10.1111/myc.13445},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-318570},
  pages     = {590 -- 598},
  year      = {2022},
  abstract  = {Candida auris was first described as a yeast pathogen in 2009. Since then, the species has emerged worldwide. In contrast to most other Candida spp., C. auris frequently exhibits multi-drug resistance and is readily transmitted in hospital settings. While most detections so far are from colonised patients, C. auris does cause superficial and life-threatening invasive infections. During management of the first documented C. auris transmission in a German hospital, experts from the National Reference Centers for Invasive Fungal Infections (NRZMyk) and the National Reference Center for Surveillance of Nosocomial Infections screened available literature and integrated available knowledge on infection prevention and C. auris epidemiology and biology to enable optimal containment. Relevant recommendations developed during this process are summarised in this guidance document, intended to assist in management of C. auris transmission and potential outbreak situations. Rapid and effective measures to contain C. auris spread require a multi-disciplinary approach that includes clinical specialists of the affected unit, nursing staff, hospital hygiene, diagnostic microbiology, cleaning staff, hospital management and experts in diagnostic mycology / fungal infections. Action should be initiated in a step-wise process and relevant interventions differ between management of singular C. auris colonised / infected patients and detection of potential C. auris transmission or nosocomial outbreaks.},
  language  = {en}
}
@article{RaschigRamirez‐ZavalaWiestetal.2023,
  author    = {Raschig, Martina and Ram{\´i}rez-Zavala, Bernardo and Wiest, Johannes and Saedtler, Marco and Gutmann, Marcus and Holzgrabe, Ulrike and Morschh{\"a}user, Joachim and Meinel, Lorenz},
  title     = {Azobenzene derivatives with activity against drug-resistant Candida albicans and Candida auris},
  series = {Archiv der Pharmazie},
  volume    = {356},
  journal   = {Archiv der Pharmazie},
  number    = {2},
  doi       = {10.1002/ardp.202200463},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-312295},
  year      = {2023},
  abstract  = {Increasing resistance against antimycotic drugs challenges anti-infective therapies today and contributes to the mortality of infections by drug-resistant Candida species and strains. Therefore, novel antifungal agents are needed. A promising approach in developing new drugs is using naturally occurring molecules as lead structures. In this work, 4,4'-dihydroxyazobenzene, a compound structurally related to antifungal stilbene derivatives and present in Agaricus xanthodermus (yellow stainer), served as a starting point for the synthesis of five azobenzene derivatives. These compounds prevented the growth of both fluconazole-susceptible and fluconazole-resistant Candida albicans and Candida auris strains. Further in vivo studies are required to confirm the potential therapeutic value of these compounds.},
  language  = {en}
}
@article{SattlerNosterBrunkeetal.2021,
  author    = {Sattler, Janko and Noster, Janina and Brunke, Anne and Plum, Georg and Wiegel, Pia and Kurzai, Oliver and Meis, Jacques F. and Hamprecht, Axel},
  title     = {Comparison of two commercially available qPCR kits for the detection of Candida auris},
  series = {Journal of Fungi},
  volume    = {7},
  journal   = {Journal of Fungi},
  number    = {2},
  issn      = {2309-608X},
  doi       = {10.3390/jof7020154},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-228879},
  year      = {2021},
  abstract  = {Candida auris is an emerging pathogen with resistance to many commonly used antifungal agents. Infections with C. auris require rapid and reliable detection methods to initiate successful medical treatment and contain hospital outbreaks. Conventional identification methods are prone to errors and can lead to misidentifications. PCR-based assays, in turn, can provide reliable results with low turnaround times. However, only limited data are available on the performance of commercially available assays for C. auris detection. In the present study, the two commercially available PCR assays AurisID (OLM, Newcastle Upon Tyne, UK) and Fungiplex Candida Auris RUO Real-Time PCR (Bruker, Bremen, Germany) were challenged with 29 C. auris isolates from all five clades and eight other Candida species as controls. AurisID reliably detected C. auris with a limit of detection (LoD) of 1 genome copies/reaction. However, false positive results were obtained with high DNA amounts of the closely related species C. haemulonii, C. duobushaemulonii and C. pseudohaemulonii. The Fungiplex Candida Auris RUO Real-Time PCR kit detected C. auris with an LoD of 9 copies/reaction. No false positive results were obtained with this assay. In addition, C. auris could also be detected in human blood samples spiked with pure fungal cultures by both kits. In summary, both kits could detect C. auris-DNA at low DNA concentrations but differed slightly in their limits of detection and specificity.},
  language  = {en}
}
@article{MayrRamirezZavalaKruegeretal.2020,
  author    = {Mayr, Eva-Maria and Ram{\´i}rez-Zavala, Bernardo and Kr{\"u}ger, Ines and Morschh{\"a}user, Joachim},
  title     = {A Zinc Cluster Transcription Factor Contributes to the Intrinsic Fluconazole Resistance of Candida auris},
  series = {mSphere},
  volume    = {5},
  journal   = {mSphere},
  number    = {2},
  doi       = {10.1128/mSphere.00279-20},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-229937},
  year      = {2020},
  abstract  = {ABSTRACT The recently emerged pathogenic yeast Candida auris is a major concern for human health, because it is easily transmissible, difficult to eradicate from hospitals, and highly drug resistant. Most C. auris isolates are resistant to the widely used antifungal drug fluconazole due to mutations in the target enzyme Erg11 and high activity of efflux pumps, such as Cdr1. In the well-studied, distantly related yeast Candida albicans, overexpression of drug efflux pumps also is a major mechanism of acquired fluconazole resistance and caused by gain-of-function mutations in the zinc cluster transcription factors Mrr1 and Tac1. In this study, we investigated a possible involvement of related transcription factors in efflux pump expression and fluconazole resistance of C. auris. The C. auris genome contains three genes encoding Mrr1 homologs and two genes encoding Tac1 homologs, and we generated deletion mutants lacking these genes in two fluconazole-resistant strains from clade III and clade IV. Deletion of TAC1b decreased the resistance to fluconazole and voriconazole in both strain backgrounds, demonstrating that the encoded transcription factor contributes to azole resistance in C. auris strains from different clades. CDR1 expression was not or only minimally affected in the mutants, indicating that Tac1b can confer increased azole resistance by a CDR1-independent mechanism. IMPORTANCE Candida auris is a recently emerged pathogenic yeast that within a few years after its initial description has spread all over the globe. C. auris is a major concern for human health, because it can cause life-threatening systemic infections, is easily transmissible, and is difficult to eradicate from hospital environments. Furthermore, C. auris is highly drug resistant, especially against the widely used antifungal drug fluconazole. Mutations in the drug target and high activity of efflux pumps are associated with azole resistance, but it is not known how drug resistance genes are regulated in C. auris. We have investigated the potential role of several candidate transcriptional regulators in the intrinsic fluconazole resistance of C. auris and identified a transcription factor that contributes to the high resistance to fluconazole and voriconazole of two C. auris strains from different genetic clades, thereby providing insight into the molecular basis of drug resistance of this medically important yeast."},
  language  = {en}
}